–
– An October 2021 photo provided by Pfizer shows vials of its COVID-19 vaccine for children in Puurs, Belgium. The special vials have an orange cap to distinguish them from the adult vaccine. HONS
–
By LAURAN NEERGAARD and MATTHEW PERRONE
Child-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective in preventing symptomatic infection in children ages 5 to 11, according to details of a company study released Friday. at a time when the US government determines whether to include that age group in the vaccination campaign.
Vaccination could begin in early November and the first children in line would be fully protected by Christmas if regulators give it the green light.
Details of the Pfizer study were published online. The Food and Drug Administration (FDA) is expected to release its independent evaluation of the safety and effectiveness of the vaccine in the next few hours.
Tucson Iron & Metal has committed to paying the equivalent of two years at Pima Community – about $ 10,000 – for each of the 38 fourth graders at Mission View Elementary.
–
–
–
–
FDA advisers will publicly debate the tests next week. If they authorize the vaccines, the Centers for Disease Control and Prevention (CDC) will have the final say on who should get them.
Pfizer maximum strength vaccines are already licensed for people 12 years and older, but pediatricians and many parents eagerly await immunization of children under that age to prevent the aggressive delta variant and allow children to go to school. .
More than 25,000 pediatricians and primary care providers have already signed up to give the injections in the small arms.
The administration of President Joe Biden has purchased enough pediatric doses – in special orange-capped vials to distinguish them from the adult vaccine – for the approximately 28 million children ages 5 to 11 in the United States. If the vaccine is approved, 11 million doses will be shipped nationwide immediately, along with needles of the corresponding size.
– .
